Let's say for the sake of argument that we are equal. The
Let's say for the sake of argument that we are equal. The future of HIV treatments would basically be split between two companies. If that the worst case, I'm just fine with that.
Obviously I would rather have all of the market share. But I keep coming back to the fact that we need revenue so we can unlock the full potential of this molecule.
That's the big prize. COVID and HIV are the means to the end for Leronlimab. A way to get to the true potential.
So, what we need is SOME revenue. Not ALL of the revenue. Please keep this in mind.
4
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
8x8, Inc. Reports Strong Earnings Amid Growth Initiatives 8x8, Inc. (NASDAQ: EGHT), the prominent cloud communications provider, has experienced a notable uptick of 2% in its share value during after-hours trading following the release of their latest quarterly earnings. The company reported second quarter results that exceeded market expectations, providing a boost in...
Continue Reading
Investors Encouraged to Join Indivior PLC Securities Fraud Lawsuit The Schall Law Firm, a well-known litigation firm dedicated to protecting shareholders' rights, is reaching out to investors about an important class action lawsuit against Indivior PLC (NASDAQ: INDV). This case concerns potential breaches of the Securities Exchange Act of 1934 and Rule 10b-5 as...
Continue Reading
McDermott Strengthens Leadership with New Board Appointments McDermott International, Ltd has made a significant strategic move by announcing the addition of two accomplished professionals, Michael Martino and Farhad Nanji, to its Board of Directors. This change is aimed at bolstering the company’s leadership as it navigates the complex landscapes of the energy...
Continue Reading
United Therapeutics Reaches New Heights in Stock Value United Therapeutics Corporation (NASDAQ: UTHR) has achieved a remarkable milestone by reaching an all-time high of $366.23. This significant increase signifies a robust period of growth for the biotech company, which has seen its stock jump by an impressive 54.22% over the past year. The surge is largely attributed to...
Continue Reading
DoorDash Reaches New Stock Heights DoorDash (NASDAQ: DASH) has experienced a remarkable surge, with its stock recently hitting a 52-week high of $181.78. This leap signifies not only a thriving business model but also a considerable increase in investor confidence in the food delivery service. With a market cap of $75.3 billion, DoorDash has shown impressive growth with a...
Continue Reading
